Table 3.
Comparison of demographic and clinical features in all 67 NK AML patients with respect to DNMT3A nonsynonymous variation status.
| Clinical characteristics | DNMT3A nonsynonymous variation status | P value | DNMT3A deleterious mutation status | P value | DNMT3A R882 mutation status | P value | |||
|---|---|---|---|---|---|---|---|---|---|
| No variation (N = 57) | Variation (N = 10) | No mutation (N = 60) | Mutation (N = 7) | No mutation (N = 62) | Mutation (N = 5) | ||||
| Sex (M : F)* | 33 : 24 | 4 : 6 | NS | 34 : 26 | 3 : 4 | NS | 35 : 27 | 2 : 3 | NS |
| Age, years, median (range)** | 56.0 (11.0–80.0) | 62.0 (18.0–83.0) | NS | 56.0 (11.0–80.0) | 59.0 (18.0–83.0) | NS | 56.0 (11.0–83.0) | 59.0 (18.0–77.0) | NS |
| Laboratory findings at diagnosis, median (range) | |||||||||
| WBC (×109/L)** | 35.6 (0.9–368.9) | 63.8 (0.6–282.2) | NS | 36.3 (0.6–368.9) | 55.5 (0.9–206.0) | NS | 33.6 (0.6–368.9) | 72.2 (0.9–206.0) | NS |
| Hb (g/dL)** | 8.6 (5.4–14.2) | 7.7 (5.6–10.7) | NS | 8.6 (5.4–14.2) | 7.3 (5.6–10.7) | NS | 8.6 (5.4–14.2) | 7.3 (5.6–10.7) | 0.097 |
| Platelets (×109/L)** | 54.0 (5.0–172.0) | 62.0 (38.0–270.0) | NS | 54.0 (5.0–172.0) | 96.0 (43.0–270.0) | NS | 53.5 (5.0–172.0) | 113.0 (51.0–270.0) | NS |
| BM blasts (%)** | 73.0 (22.1–97.0) | 74.3 (29.5–96.2) | NS | 72.9 (22.1–97.0) | 75.0 (29.5–84.3) | NS | 72.9 (22.1–97.0) | 75.0 (29.5–84.3) | NS |
| FLT3 ITD mutation (%)* | 11/45 (24.4) | 4/6 (66.7) | 0.054 | 12/47 (25.5) | 3/4 (75.0) | 0.071 | 12/47 (25.5) | 3/4 (75.0) | 0.071 |
| FLT3 D835 mutation (%)* | 2/45 (4.4) | 0/6 (0.0) | NS | 2/47 (4.3) | 0/4 (0.0) | NS | 2/47 (4.3) | 0/4 (0.0) | NS |
| CR rates (%)* | 33/57 (57.9) | 3/10 (30.0) | NS | 34/60 (56.7) | 2/7 (28.6) | NS | 34/62 (54.8) | 2/5 (40.0) | NS |
| Interval from Dx to CR, days, median (range)** | 34.0 (21.0–83.0) | 53.0 (25.0–164.0) | NS | 35.0 (21.0–164.0) | 39.0 (25.0–53.0) | NS | 35.0 (21.0–164.0) | 39.0 (25.0–53.0) | NS |
| Relapse rates (%)* | 16/33 (48.5) | 1/3 (33.3) | NS | 17/34 (50.0) | 0/2 (0.0) | NS | 17/34 (50.0) | 0/2 (0.0) | NS |
| Death rates (%)* | 31/57 (54.4) | 5/10 (50.0) | NS | 34/60 (56.7) | 2/7 (28.6) | NS | 34/62 (54.8) | 2/5 (40.0) | NS |
| SCT performance rates (%)* | 19/57 (33.3) | 1/10 (10.0) | NS | 19/60 (31.7) | 1/7 (14.3) | NS | 19/62 (30.6) | 1/5 (20.0) | NS |
Note: P values were obtained from Chi-square test/Fisher's exact test* and Mann-Whitney U test**.
WBC: white blood cell; Hb: hemoglobin; BM: bone marrow; FLT3: fms-related tyrosine kinase 3; ITD: internal tandem duplications; D: aspartate; CR: complete remission; Dx: diagnosis; SCT: stem cell transplantation; DNMT3A: DNA methyltransferase 3A; R: arginine; NS: not significant.